EUA Transition Process: 4 Things FDA Wants You To Know
A US FDA regulatory expert offers insight into what companies can expect from the agency as it braces to transition potentially hundreds of emergency use authorized (EUA) products to full marketing authorization.
You may also be interested in...
The US agency’s device center on 26 October published its A and B lists of guidance documents it will prioritize in fiscal year 2022, including drafting guidances to transition emergency use authorized products to full marketing status, and finalizing a clinical decision support software guidance that’s been four years in the making.
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.